The conversion eliminates $2.0M of debt but at the cost of extreme dilution (~369% increase in shares outstanding). With the shares registered for resale, the holder can sell immediately, creating significant near-term selling pressure. Monitor the stock price and volume for the next several trading sessions.
Price Chart
Executive Summary
SciSparc entered into an inducement letter with L.I.A Pure Capital Ltd. to convert $2,023,039.21 of outstanding convertible note principal and accrued interest into ordinary shares at $1.50 per share. The conversion is non-cash (no proceeds to the company) and the resale of the shares is registered on an effective F-3 shelf. This eliminates $2.0M of debt but immediately dilutes existing shareholders by approximately 1,348,693 new shares (based on the conversion price), representing a massive increase over the 365,444 shares outstanding as of December 31, 2025.
Key Facts
- SciSparc induced L.I.A Pure Capital to convert $2,023,039.21 of convertible note principal and accrued interest into ordinary shares at $1.50 per share.
- No cash proceeds to SciSparc from the conversion.
- The conversion price of $1.50 per share implies the issuance of approximately 1,348,693 new ordinary shares.
- As of December 31, 2025, SciSparc had only 365,444 ordinary shares outstanding, meaning the conversion would increase the share count by roughly 369%.
- The resale of the conversion shares is registered on an effective Form F-3 shelf (File No. 333-293533), allowing immediate resale by the holder.
- The holder is subject to a 4.99% beneficial ownership limitation, which may delay issuance of a portion of the shares.
- The closing is expected on or about October 16, 2026.
Financial Impact
Debt elimination of $2,023,039.21 offset by massive dilution: ~1.35M new shares issued vs. 365K shares outstanding pre-conversion (369% increase). No cash proceeds.
Risk Factors
- Massive dilution: share count increases by ~369%, severely diluting existing shareholders.
- Immediate resale overhang: the holder can sell the newly issued shares into the market without restriction, likely pressuring the stock price.
- No cash infusion: the conversion provides no new capital to fund operations or clinical trials.
- Potential for further dilution: the beneficial ownership limitation may only delay, not prevent, full conversion.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-109727 |
| Document: ea030875201ex10-1.htm | 0001213900-26-109727 |
| Document: 0001213900-26-109727-index-headers.html | 0001213900-26-109727 |
| Document: 0001213900-26-109727-index.html | 0001213900-26-109727 |
| Document: 0001213900-26-109727.txt | 0001213900-26-109727 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers